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Problem Identification
Opioid overdoses are a growing public health concern in Vermont.
 Between 2012 and 2017, the number of fatal opioid overdoses in Vermont nearly doubled, from 
51 to 101.1
 Of all Vermont counties, Franklin County has the 3rd highest rate of fatal opioid overdoses. 1
 Nationally, up to 49% of adults personally know someone who has faced opioid addiction, and 
10% know someone who has died because of it. 2
Naloxone can save lives… if people know how to use it.
 Only 20% of American adults know what naloxone is; that it can be given by a layperson; and that 
it is available without a prescription. 3
 When informed about naloxone, up to 68% would be willing to use it to help someone who had 
overdosed. 3
 For every overdose fatality in Vermont, 5 other people are saved by community-administered 
naloxone. 4
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Public Health Cost
“[P]revious estimates of the economic cost of the opioid crisis greatly understate it by 
undervaluing the most important component of the loss – fatalities resulting from 
overdoses.”
--White House Council of Economic 
Advisors5
 In 2015, opioid overdoses killed 41,033 people in the United States. The White House Council of 
Economic Advisors estimates the “cost” of these deaths at $431.7 billion. 5
 The cost of two units of Narcan (naloxone nasal spray) is approximately $150. 6
 A 2013 NIAID study found that naloxone distribution to heroin users was cost-effective, with an 
incremental cost effectiveness ratio of $14,000 in the most conservative scenario. 7
 More recent data from Vermont indicate much greater cost effectiveness. In 2018, one Vermont social 
service agency that distributes naloxone kits estimated a cost per life saved of $325-$450.8
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Community Perspective
Interview with Karen Heinlein-Grenier, Katie DeForge, and Maria Carlson, staff at Turning 
Point Center of Franklin County:
 Turning Point has distributed free Narcan for 4 years, and has noted steadily increasing interest during 
that time.
 Requests for Narcan come from a mixture of active users, people in treatment/recovery, and non-users.
 They do not always have follow-up with people who receive Narcan kits, so are not sure how often kits 
are used.
 Recently they have seen more requests from elderly people, and more people referred by healthcare 
providers.
 People may find it difficult to get Narcan from a pharmacy because:
 They are concerned about stigma from pharmacists and other customers, and lack of privacy at the 
pharmacy counter.
 They worry that asking for Narcan will broadcast that they have opioids and make them a target.
 They do not know that it is available without a prescription, how much it will cost, or whether insurance 
will cover it. 4
Community Perspective, continued
Interview with Karen Heinlein-Grenier, Katie DeForge, and Maria Carlson, staff at 
Turning Point Center of Franklin County:
 It is beneficial for people to carry Narcan even if they don’t know of anyone who abuses 
opioids:
 If someone in their home has an opioid prescription, they may accidentally take an excess dose 
because of memory decline or polypharmacy; or a child may gain access to the medication.
 A friend, family member, or coworker may be a “closet user.”
 Opioids may be cut into other drugs, such as marijuana or cocaine.
 People may encounter someone who has overdosed in a public setting – for example, slumped over 
the steering wheel in a parking lot.
 Interviewees were enthusiastic about the idea of incorporating naloxone education into 
routine primary care encounters, noting that this could provide the opportunity to educate 
a “captive audience” and may have a positive normalizing effect.
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Intervention & Methodology
 During the course of routine primary care visits, patients who were not being 
prescribed opioids or receiving treatment for opioid use disorder were asked:
“Many of our patients have friends and family who are affected by the opioid epidemic. 
There is a medication called naloxone that you could use to save a life if someone around 
you were to overdose. Would you like to learn more about naloxone while you’re 
here today?”
 Patients who consented were instructed in how to use Narcan and given:
 A quick reference sheet summarizing when and how to use Narcan nasal spray, and what to 
do afterward
 A list of local organizations that distribute free Narcan kits, and local pharmacies with prices
 The reference sheet was developed based on similar resources from the CDC, 
Vermont Department of Health, and the Narcan package insert, and has a Flesch-
Kincaid grade level of 3.4 (i.e., a 3rd grade reading level).
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Results
 Over the course of 7 days in clinic, naloxone education was offered to all patients who 
were not receiving opioid prescriptions – a total of 7 patients; 2 said yes (28%).
 After naloxone education:
 100% said that they plan to obtain naloxone.
 100% said that they would not be surprised if they witnessed an overdose in the next 12 
months.
 100% said that they would feel confident about administering naloxone if necessary.
 Patient feedback:
 “Honestly, you really never know when you might need this” – recently passed a driver 
who was pulled over unconscious with a child in the car, and called 911, but would have used 
naloxone if she’d had it
 Had heard of Narcan but “I had no idea that anyone can get it, or that it’s so simple to use – this 
is definitely life-changing information”
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Evaluation & Limitations
Although naloxone education was well-received by those patients who received it, the number of patients 
participating in this project was very small, for three reasons:
1.    The duration of the project was very short.
2.    The vast majority of patients encountered were not part of the target group for this 
project, because they were receiving opioids (either as a component of medication-assisted treatment or 
for chronic pain).
3.    Almost three-quarters of eligible patients declined naloxone education, largely because they 
did not perceive it as personally relevant.
 Most declined because to their knowledge, none of their friends or family members used opioids.
 One patient has a household member who is prescribed opioids, but did not perceive him to be at risk 
of overdose.
 One patient stated that he did not believe that people who overdose should be revived.
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Future Recommendations
Potential directions for future work in this area include:
 Conducting a longer trial of this project, possibly in a different population in which 
fewer patients are being prescribed opioids.
 Develop materials that convey to patients that even if they do not know of friends or 
family who abuse opioids, they may still be in a position to save someone’s life.
 Determine demographic characteristics of patients who are more likely to consent to 
naloxone education, and develop recommendations regarding who should be offered 
naloxone education, when, and how often.
 Initiate collaboration with the Vermont Department of Health or other community 
agencies in order to distribute free Narcan kits from the office.
 Hold focus groups with community members to identify other needs and strategies 
for supporting family and friends of opioid users in a primary care setting.
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Interview Consent
Thank you for agreeing to be interviewed. This project is a requirement for the 
Family Medicine clerkship. It will be stored on the Dana Library ScholarWorks
website. Your name will be attached to your interview and you may be cited directly 
or indirectly in subsequent unpublished or published work. The interviewer affirms 
that he/she has explained the nature and purpose of this project. The interviewee 
affirms that he/she has consented to this interview. Yes _X__ / No _____
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